Fluidigm Corporation (NASDAQ:FLDM) today announced that Gerhard F. Burbach has been appointed to Fluidigm’s Board of Directors. Mr. Burbach will also join the Board’s Audit and Compensation Committees.
“We are extremely pleased to have a seasoned executive of Gary Burbach’s caliber joining the board of Fluidigm. Gary has extensive operating experience, as well as strong strategic skills and expertise that we believe will contribute to the continued success of Fluidigm,” said Sam Colella, Fluidigm Chairman of the Board.
“Fluidigm is leading the charge into single-cell genomics. The company’s extraordinary proprietary microfluidic technology automates the single-cell workflow and lowers costs so that groundbreaking research in this exciting new field becomes readily achievable. I look forward to joining Fluidigm’s Board of Directors and working with the management team to bring these significant opportunities to reality,” said Mr. Burbach.
Mr. Burbach currently serves as president, chief executive officer and director of Thoratec Corporation, a publicly-traded company that develops, manufactures and markets proprietary medical devices used for circulatory support.Mr. Burbach has extensive experience in the medical technology industry. Prior to joining Thoratec Corporation in January 2006, he served as president and chief executive officer of Digirad Corporation from April 2005 to January 2006. He also has been a member of Digirad’s board of directors since 2004. From July 2003 to April 2005, Mr. Burbach served as president and chief executive officer of Bacchus Vascular, Inc., a developer of catheter-based medical devices. From January 2001 to July 2003, he served as chief executive officer of Philips Nuclear Medicine, a division of Philips Electronics, and, before its acquisition by Philips, worked for four years for ADAC Laboratories, most recently as president. Mr. Burbach also spent six years with the management consulting firm of McKinsey & Company, Inc., where he was most recently a senior engagement manager in the firm’s healthcare practice.